Genelux Corp (GNLX) — SEC Filings
Genelux Corp (GNLX) — 29 SEC filings. Latest: ARS (Apr 29, 2026). Includes 13 8-K, 6 10-Q, 2 DEF 14A.
View Genelux Corp on SEC EDGAR
Overview
Genelux Corp (GNLX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: GENELUX Corp reported a net loss of $22.9 million for the nine months ended September 30, 2025, an increase from $20.9 million for the same period in 2024. The company generated no revenue in the current nine-month period, compared to $8,000 in 2024. Research and development expenses rose to $14.2 m
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral. The dominant filing sentiment for Genelux Corp is neutral.
Filing Type Overview
Genelux Corp (GNLX) has filed 1 ARS, 1 DEFA14A, 6 10-Q, 13 8-K, 2 DEF 14A, 1 10-K/A, 2 10-K, 2 SC 13G, 1 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of GNLX's 17 recent filings, 2 were flagged as high-risk, 3 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$22.9M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $4.7M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. David L. Sidransky
- John Thomas
- James Tyree
- Sean Ryder
- Paul Scigalla
Industry Context
The biotechnology sector, particularly companies focused on novel therapeutics like GENELUX, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success is heavily dependent on clinical trial outcomes and subsequent market adoption. The competitive landscape is intense, with many companies vying for funding and market share.
Top Tags
corporate-governance (5) · Pharmaceuticals (4) · 10-Q (3) · Biotechnology (2) · shareholder-vote (2) · pharmaceuticals (2) · financials (2) · governance (2) · 8-K (2) · regulation-fd (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $22.9M | Increased from $20.9M in prior year, indicating worsening financial performance. |
| Cash Used in Operations | $19.1M | Increased from $16.9M, highlighting accelerated cash burn. |
| Cash, Cash Equivalents & Restricted Cash | $4.7M | Significant decrease from $8.6M, raising liquidity concerns. |
| Short-term Investments | $16.2M | Decreased from $22.3M, further reducing available capital. |
| Revenue | $0 | No revenue generated in the current nine-month period, emphasizing reliance on financing. |
| Research and Development Expenses | $14.2M | Increased from $12.5M, reflecting ongoing investment in Olvi-Vec. |
| Shares Outstanding | 38,051,771 | As of October 30, 2025, indicating potential dilution from equity financing. |
| Estimated Cash Runway | Q3 2026 | Company expects existing cash to fund operations only into this quarter. |
| Commission File Number | 001-41599 | Identifies the company's SEC filing series. |
| I.R.S. Employer Identification No. | 77-0583529 | Company's tax identification number. |
| Number of Class III directors to be elected | 2 | These directors will serve until the 2028 Annual Meeting. |
| Fiscal year for auditor appointment | 2025 | Weinberg & Company, P.A. is appointed for the fiscal year ending December 31, 2025. |
| Annual Meeting Date | August 27, 2025 | The virtual meeting will be held at 10:00 a.m. Pacific Time. |
| Record Date | June 30, 2025 | Stockholders of record on this date can vote at the Annual Meeting. |
| Fiscal Year End | 2024-12-31 | The period covered by the annual report. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Genelux Corp (GNLX)?
Genelux Corp has 29 recent SEC filings from Feb 2024 to Apr 2026, including 13 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GNLX filings?
Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral. The dominant sentiment is neutral.
Where can I find Genelux Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Genelux Corp (GNLX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Genelux Corp?
Key financial highlights from Genelux Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GNLX?
The investment thesis for GNLX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Genelux Corp?
Key executives identified across Genelux Corp's filings include Dr. David L. Sidransky, John Thomas, James Tyree, Sean Ryder, Paul Scigalla.
What are the main risk factors for Genelux Corp stock?
Of GNLX's 17 assessed filings, 2 were flagged high-risk, 3 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Genelux Corp?
Forward guidance and predictions for Genelux Corp are extracted from SEC filings as they are enriched.